A team-guided immunotherapy plan got most borderline lung cancer patients to curative care
In the phase 2 MDT-BRIDGE trial, published Oct. 26, 2026, in Nature Medicine, 142 people with resectable or borderline lung cancer got durvalumab plus chemotherapy before surgery; 74.6% had their tumor removed…